http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Brigatinib versus Crizotinib in <i>ALK</i>-Positive Non-Small-Cell Lung Cancer
Camidge, D. Ross,Kim, Hye Ryun,Ahn, Myung-Ju,Yang, James Chih-Hsin,Han, Ji-Youn,Lee, Jong-Seok,Hochmair, Maximilian J.,Li, Jacky Yu-Chung,Chang, Gee-Chen,Lee, Ki Hyeong,Gridelli, Cesare,Delmonte, Ange New England Journal of Medicine 2018 The New England journal of medicine Vol.379 No.21
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, Ghassan K.,Meyer, Tim,Cheng, Ann-Lii,El-Khoueiry, Anthony B.,Rimassa, Lorenza,Ryoo, Baek-Yeol,Cicin, Irfan,Merle, Philippe,Chen, YenHsun,Park, Joong-Won,Blanc, Jean-Frederic,Bolondi, Luigi New England Journal of Medicine 2018 The New England journal of medicine Vol.379 No.1
<P>Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group.</P>
<i>Helicobacter pylori</i> Therapy for the Prevention of Metachronous Gastric Cancer
Choi, Il Ju,Kook, Myeong-Cherl,Kim, Young-Il,Cho, Soo-Jeong,Lee, Jong Yeul,Kim, Chan Gyoo,Park, Boram,Nam, Byung-Ho New England Journal of Medicine 2018 The New England journal of medicine Vol.378 No.12
<P>Patients with early gastric cancer who received H. pylori treatment had lower rates of metachronous gastric cancer and more improvement from baseline in the grade of gastric corpus atrophy than patients who received placebo.</P>
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Smith, Matthew R.,Saad, Fred,Chowdhury, Simon,Oudard, Sté,phane,Hadaschik, Boris A.,Graff, Julie N.,Olmos, David,Mainwaring, Paul N.,Lee, Ji Youl,Uemura, Hiroji,Lopez-Gitlitz, Angela,Trudel, G&e New England Journal of Medicine 2018 The New England journal of medicine Vol.378 No.15
<P>Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo.</P>